Table 2.
Clinical trials investigating therapeutic approaches targeting inflammation and immunomodulatory effects in cancers often driven by KRAS mutations.
| Target(s) | Trial number | Phase | Drug(s) | Combination drug(s) | Cancer type | Current status |
|---|---|---|---|---|---|---|
| IL-6 and PD-1 | NCT04191421 | I/II | Siltuximab (CNTO 328) and Spartalizumab (PDR001) | — | Metastatic pancreatic cancer | Recruiting |
| IL-8 | NCT02536469 | I | BMS-986253 (HuMax-IL-8) | — | Advanced malignant solid tumours | Completed |
| IL-8 and PD-1 | NCT04123379 | II | Anti-IL-8 | Nivolumab | NSCLC and HCC | Recruiting |
| IL-1R | NCT00072111 | I | Anakinra | — | Metastatic cancer | Completed |
| IL-1RAP | NCT03267316 (CANFOUR) | I/II | CAN04 | — | Solid tumours | Recruiting |
| IL-1β | NCT03447769 - (CANOPY-A) | III | Canakinumab | — | NSCLC | Recruiting |
| IL-1β and/or PD-1 | NCT03968419 - (CANOPY-N) | II | Canakinumab and/or pembrolizumab | — | NSCLC | Recruiting |
| IL-1β and/or PD-1 | NCT03631199 - (CANOPY-1) | III | Canakinumab and/or pembrolizumab | Platinum-based doublet chemotherapy | NSCLC | Active, not recruiting |
| IL-1β | NCT03626545 - (CANOPY-2) | III | Canakinumab | Docetaxel | NSCLC | Active, not recruiting |
| IL-1β and PD-1 | NCT03064854 | I | Spartalizumab (PDR001) and canakinumab | Platinum-doublet chemotherapy | NSCLC | Active, not recruiting |
| PD-1 and IL-17 or IL-1β | NCT02900664 | I | Spartalizumab (PDR001) and CJM112 or canakinumab | Trametinib | CRC, TNBC, NSCLC | Active, not recruiting |
| PD-1 | NCT01295827 (KEYNOTE-001) | I | Pembrolizumab | — | Metastatic carcinoma, melanoma, or NSCLC | Completed |
| PD-1 | NCT02130466 | I/II | Pembrolizumab | Trametinib, dabrafenib | Advanced melanoma and solid tumours | Active, not recruiting |
| PD-L1 | NCT02908672 (IMspire150) | III | Atezolizumab | Cobimetinib, vemurafenib | Metastatic or unresectable locally advanced melanoma | Active, not recruiting |
| ICAM and PD-1 | NCT02043665 | I | CVA21 (Coxsackievirus) and Pembrolizumab | — | NSCLC and bladder cancer | Completed |
| ICAM and PD-1 | NCT02824965 | I/II | CVA21 (Coxsackievirus) and pembrolizumab | — | NSCLC | Active, not recruiting |
| JAK1/2 | NCT02244489 | I | Momelotinib | Capecitabine and oxaliplatin | PDAC | Terminated |
CRC colorectal cancer, HCC hepatocellular carcinoma, ICAM intercellular adhesion molecule, IL-1RAP interleukin-1 receptor accessory protein, IL-1β interleukin-1β, IL-6 interleukin-6, IL-8 interleukin-8, JAK1/2 Janus activated kinase 1/2, NSCLC non-small-cell lung cancer, PD-1 programmed cell death protein 1, PDAC pancreatic ductal adenocarcinoma, PD-L1 programmed death-ligand-1, TNBC triple-negative breast cancer.